Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW 2: Cagrilintide for Weight Management in Overweight/Obesity and Type 2 Diabetes
NCT07220759Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of cagrilintide in obesity, sponsored by Novo Nordisk. Started Nov 2025; status: active, not recruiting.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07220759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220759.